Daniela Pietrasanta

560 total citations
19 papers, 244 citations indexed

About

Daniela Pietrasanta is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Daniela Pietrasanta has authored 19 papers receiving a total of 244 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 8 papers in Pathology and Forensic Medicine and 7 papers in Hematology. Recurrent topics in Daniela Pietrasanta's work include Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (8 papers) and CNS Lymphoma Diagnosis and Treatment (3 papers). Daniela Pietrasanta is often cited by papers focused on Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (8 papers) and CNS Lymphoma Diagnosis and Treatment (3 papers). Daniela Pietrasanta collaborates with scholars based in Italy, Switzerland and United States. Daniela Pietrasanta's co-authors include Alessandro Levis, Anna Baraldi, Mario Boccadoro, Flavia Salvi, Marino Clavio, Eugenio Gallo, Umberto Vitolo, Paolo Gavarotti, Delia Rota Scalabrini and Anna Tonso and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Daniela Pietrasanta

19 papers receiving 239 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniela Pietrasanta Italy 7 121 102 78 68 60 19 244
R.B. Berryman United States 8 111 0.9× 92 0.9× 104 1.3× 26 0.4× 40 0.7× 16 237
Sujaatha Narayanan Canada 10 63 0.5× 181 1.8× 61 0.8× 67 1.0× 81 1.4× 43 272
Ruemu Birhiray United States 8 80 0.7× 71 0.7× 80 1.0× 50 0.7× 81 1.4× 32 241
Giacinto La Verde Italy 9 107 0.9× 191 1.9× 157 2.0× 141 2.1× 65 1.1× 27 344
Ana Isabel Teruel Spain 7 60 0.5× 79 0.8× 59 0.8× 41 0.6× 53 0.9× 24 194
Claudia Minotto Italy 9 110 0.9× 92 0.9× 62 0.8× 56 0.8× 122 2.0× 14 252
Alessandra Cuttica Italy 8 204 1.7× 87 0.9× 147 1.9× 19 0.3× 80 1.3× 10 287
Pat Stiff United States 7 73 0.6× 90 0.9× 89 1.1× 19 0.3× 68 1.1× 13 208
Florence Broussais‐Guillaumot France 9 228 1.9× 45 0.4× 153 2.0× 27 0.4× 95 1.6× 14 305
Jahanzaib Khwaja United Kingdom 9 95 0.8× 60 0.6× 32 0.4× 45 0.7× 99 1.6× 42 253

Countries citing papers authored by Daniela Pietrasanta

Since Specialization
Citations

This map shows the geographic impact of Daniela Pietrasanta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniela Pietrasanta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniela Pietrasanta more than expected).

Fields of papers citing papers by Daniela Pietrasanta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniela Pietrasanta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniela Pietrasanta. The network helps show where Daniela Pietrasanta may publish in the future.

Co-authorship network of co-authors of Daniela Pietrasanta

This figure shows the co-authorship network connecting the top 25 collaborators of Daniela Pietrasanta. A scholar is included among the top collaborators of Daniela Pietrasanta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniela Pietrasanta. Daniela Pietrasanta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Pietrasanta, Daniela, et al.. (2023). The role of Bruton’s kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib. Journal of Basic and Clinical Physiology and Pharmacology. 34(3). 401–404. 3 indexed citations
2.
Frustaci, Anna Maria, Marco Montillo, Davide Rossi, et al.. (2023). S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME. HemaSphere. 7(S3). e6990566–e6990566. 1 indexed citations
3.
Frustaci, Anna Maria, Marco Montillo, Davide Rossi, et al.. (2023). EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME. Hematological Oncology. 41(S2). 62–63. 2 indexed citations
4.
Pietrasanta, Daniela, Alessia Castellino, Federico Monaco, et al.. (2023). Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice. Cancers. 15(22). 5397–5397. 6 indexed citations
5.
Frustaci, Anna Maria, Marco Montillo, Davide Rossi, et al.. (2023). Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.. Journal of Clinical Oncology. 41(16_suppl). 7502–7502. 5 indexed citations
6.
Griggio, Valentina, Candida Vitale, Francesca Romana Mauro, et al.. (2019). Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. Blood. 134(Supplement_1). 3031–3031. 4 indexed citations
7.
Griggio, Valentina, Candida Vitale, Maria Chiara Todaro, et al.. (2018). Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. Blood. 132(Supplement 1). 4412–4412. 2 indexed citations
8.
Monaco, Federico, Massimo Pini, Michela Di Salvio, et al.. (2014). Prognostic Impact of p190 and p210 Co-Expression at Diagnosis in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib. Blood. 124(21). 5528–5528. 2 indexed citations
9.
Salvi, Flavia, Anna Baraldi, Daniela Pietrasanta, et al.. (2011). Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C. Leukemia Research. 35(8). 991–997. 34 indexed citations
10.
Levis, Alessandro, Daniela Pietrasanta, Laura Godio, et al.. (2004). A Large-Scale Study of Bone Marrow Involvement in Patients with Hodgkin's Lymphoma. Clinical Lymphoma. 5(1). 50–55. 31 indexed citations
11.
Levis, Alessandro, Alessandro Anselmo, Alberto Ambrosetti, et al.. (2003). VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Annals of Oncology. 15(1). 123–128. 51 indexed citations
12.
Levis, Alessandro, et al.. (2002). Treatment of Elderly Hodgkin's Lymphoma Patients. The Experience of the Italian Lymphoma Intergroup. Tumori Journal. 88(1_suppl1). S29–S31. 3 indexed citations
13.
Miglino, María Angélica, Giovanni Berisso, Rosario Francesco Grasso, et al.. (2002). Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse. Bone Marrow Transplantation. 30(9). 579–585. 23 indexed citations
14.
Miglino, Maurizio, Gino Santini, Raffaella Grasso, et al.. (2001). Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin's lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation.. PubMed. 86(7). 706–14. 4 indexed citations
15.
Baraldi, Anna, Daniela Pietrasanta, B Allione, et al.. (2000). Low-dose of thalidomide in the treatment of refractory myeloma.. PubMed. 85(10). 1111–2. 21 indexed citations
16.
Pierri, Ivana, Marino Clavio, Giovanni Beltrami, et al.. (1999). GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly.. PubMed. 18(1). 55–60. 2 indexed citations
17.
Clavio, Marino, María Angélica Miglino, Mauro Spriano, et al.. (1998). First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease. European Journal Of Haematology. 61(3). 197–203. 22 indexed citations
18.
Pietrasanta, Daniela, et al.. (1997). Long-lasting effect of cyclosporin-A on anemia associated with idiopathic myelofibrosis.. PubMed. 82(4). 458–9. 6 indexed citations
19.
Clavio, Marino, Salvatore Casciaro, Mauro Spriano, et al.. (1996). Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients.. PubMed. 81(3). 238–44. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R.B. Berryman Breakdown of academic impact, for papers by Sujaatha Narayanan Breakdown of academic impact, for papers by Ruemu Birhiray Breakdown of academic impact, for papers by Giacinto La Verde Breakdown of academic impact, for papers by Ana Isabel Teruel Breakdown of academic impact, for papers by Claudia Minotto Breakdown of academic impact, for papers by Alessandra Cuttica Breakdown of academic impact, for papers by Pat Stiff Breakdown of academic impact, for papers by Florence Broussais‐Guillaumot Breakdown of academic impact, for papers by Jahanzaib Khwaja
Rankless by CCL
2026